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AIDS was first reported in 1981 by Gottlieb MS et al at USC 
(University of California) Medical Center: Healthy homosexual 
men with pneumocystis carinii pneumonia and mucosal can-
didiasis had deficiency in CD4 T lymphocyte, a critical im-
mune defense cell (1). In 1983, Dr. F. Barré-Sinoussi and L. 
Montagnier isolated a new human T-lymphotropic retrovirus, 
later  named  HIV-1(human  immunodeficiency  virus  type  1) 
which  turned  out  to  be  one  of  the  causes  of  AIDS  (2). 
Through their discovery, they received the 2008 Nobel Prize 
in  Physiology  or  Medicine  award. 
  D i s c o v e r y  o f  t h e  c a u s a t i v e  a g e n t  o f  A I D S  h a d  b e e n  t h e  
driving  force  to  investigate  its  genomic  structure,  function, 
and  replication  mechanism.  Most  importantly,  the  develop-
ment  of  a  diagnostic  kit  contributed  to  the  knowledge  of 
AIDS  as  an  infectious  disease  especially  in  the  route  of 
transmission.  In  addition,  the  development  of  antiretroviral 
drugs reduced the mortality of some HIV-infected individuals. 
H o w e v e r ,  h i g h  p r i c e  a n d  s i d e  e f f e c t s  o f  t h e  c u r r e n t  t h e r -
apeutic  drugs  have  not  been  beneficial  for  most  AIDS 
patients. Thus, it has been generally accepted that the devel-
opment of a low price and effective prophylactic AIDS vac-
cine is the only answer to stop the global epidemic. Despite 
tremendous efforts over the past 25 years, there is no promis-
ing candidate for an HIV vaccine. No one has even been able 
to  design  and  develop  a  model  leading  to  an  effective 
vaccine. This review will introduce four major milestones in 
AIDS vaccine development to date which resulted in major 
social,  economic  and  scientific  impacts  (Fig.  1). 
    In 1989, the hopes for a HIV vaccine started from a highly 
effective  formalin-inactivated  whole  SIV  vaccine  which  was 
known  to  confer  protection  in  macaques  with  AIDS  (3). 
However, three years later, it was found that the protective 
effect  was  mediated  by  antigens  (such  as  HLA  and  β2m) 
from  the  human  cells  used  to  grow  the  viral  strain  (4).
    In 1992, Dr. Ronald Desrosiers reported that a live attenu-
ated SIV vaccine with a deletion in the nef gene can be effi-
cient in treating AIDS of macaques (5). Unfortunately, three 
years later, Dr. Ruth Ruprecht found that this live attenuated 
vaccine had a safety issue in which the vaccine itself caused 
AIDS in neonatal macaques. For this reason, research into the 
development of a live attenuated vaccine has been no longer 
carried  out  (6). 
    In 1990, Genentech reported that their recombinant glyco-
protein  gp120  subunit  vaccine  could  induce  protection  in 
chimpanzees with HIV-1 (7). In phase I and II trial, they con-
firmed the safety and immunogenicity. However, when this 
vaccine was tested on 5,000 volunteers to test efficacy, vacci-
nation failed to show reduction in HIV and thus was not able 
to  become  commercialized  (8). 
    Finally,  Merck  Co.  reported  that  replication-incompetent 
adenoviral vaccine could elicit effective anti-viral T cell im-
mune response against SHIV (pathogenic HIV-1 and SIV hy-
brid virus) in 2002 (9). Based on this positive result in mon-
keys, they entered clinical trial to evaluate the efficacy with 
almost 10,000 HIV-1 negative healthy volunteers. Disappoin-
tedly, in November 2007, they announced negative results on 
the interim report with 3,000 volunteers. This vaccine was in-
effective  in  lowering  plasma  viremia  postinfection  and  in-
creased the risk of acquiring HIV-1 infection; therefore, fur-
ther  study  on  the  vaccine  was  not  pursued  (10). 
    There  were  five  major  vaccines  introduced  as  possible 
treatments  for  AIDS:  killed  vaccine,  live-attenuated  vaccine, 
subunit vaccine, vectored vaccine, and DNA vaccine (Table 
I). Among them, DNA vaccine is the most promising AIDS Perspectives for a Protective AIDS Vaccine
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Figure 1. Time lines for HIV/AIDS 
pandemic and the development for 
AIDS vaccines.
Table I. The Potential of the five major AIDS vaccine candidates
Approach Immunity Safety Eficacy test
Whole inactivated
Live attenuated
Recombinant protein
Vectored vaccine
DNA
Antibody, T cell response
Antibody, T cell response
Antibody
Antibody, T cell response
Antibody, T cell response
＋/−
−
＋
＋/−
＋
Failed
Success
Failed
Failed
N/T*
*N/T: Not tested, ＋: Safe, ＋/−: Mild concerns, −: Serious concerns
vaccine since it was the only one that could provide a safe 
and protective immunity against HIV. Despite the safety con-
cerns of the live attenuated vaccine, it is currently the only 
vaccine  that  is  capable  of  inducing  a  protective  immunity. 
Hence, the  vaccine that has  similar qualities  and induces  a 
strong response of the immune system similar to that of the 
live attenuated vaccine is the most probable to become a suc-
cessful AIDS vaccine. In this regard, the fact that the DNA 
vaccine with electroporation (EP) does not have a vectored 
immunity makes it an excellent candidate because it can in-
duce  antibodies  and  a  T  cell  response  by  continuous  in-
jections which are as powerful as live the attenuated vaccine. 
Therefore, there are high expectations for DNA vaccine with 
EP to develop successful AIDS vaccines commercially avail-
able  in  the  near  future.
    In order to develop an effective DNA vaccine with EP, the 
vaccine  candidate  should  be  evaluated  thoroughly  in  terms 
of protective immunity in a small number of volunteers be-
fore entering large-scale phase IIb~III efficacy trials. More im-
portantly,  even  before  considering  any  clinical  trials  in  hu-
mans, the efficacy test should be evaluated in the appropriate 
SIVmac-rhesus  macaque  challenge  model  that  closely  re-
sembles  the  human  case. 
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